NAD+ therapy to boost brown fat metabolism in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study gives participants either an NAD+ precursor or a placebo and measures effects on brown adipose tissue using PET/CT imaging alongside metabolic testing. Participants are sedentary adults aged 30–55 and include both normal-weight subjects and people with central obesity. The design compares treatment to placebo to see changes in brown fat metabolism and whole-body insulin sensitivity. Results will clarify whether NAD+-based molecular therapies could be a viable approach to improving metabolic health in humans.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willingness to provide informed consent to participate in the BATNAD study
* Must be able to read and speak English/Finnish/Swedish well enough to completely understand the instructions and provide informed consent
* Age 30-55 (sedentary lifestyle)
* BMI = 18-25 kg/m2 (normal-weight subjects)
* BMI ≥ 28 kg/m2 and waist circumference more than 100 cm in men and more than 90 cm in women (subjects with obesity)

Exclusion Criteria:

* Inability to have PET/CT (claustrophobia, metal implants, recent tattoo including metal components, weight \> 200 kg)
* Pregnancy and pregnancy related conditions (postpartum/lactation during the last 12 months, or planning to become pregnant soon)
* Major alterations in the menstrual cycle (e.g., amenorrhea)
* Use of nicotine based products
* Hypo- or hyper- thyroidism (medical history, TSH, T3 or T4 levels out of the normal range)
* Diabetes mellitus (fasting Hb1Ac \>6.5% or fasting glycaemia\> 7.0 mmol/)
* Abnormal oral glucose tolerance test (2h OGTT \> 11.1 mmol/L)
* Hypertension (blood pressure \> 160/100 mmHg)
* Abnormal cardiovascular status (arrhythmia and/or long QTc in ECG, abnormal cardiac murmur, previous history of cardiovascular disease)
* Abnormal coagulopathy (e.g., clotting abnormality)
* Malignancies
* Immunological, autoimmune and primary/secondary immunodeficiency disorders (including or not any active treatment)
* Virus or bacterial infection (both asymptomatic and symptomatic picture) within the 45 days prior to the study start
* Vaccination within the 45 days prior to the study start
* Episode of fever or major surgery, burns and traumas within the month prior to the study start
* Chronic infections requiring chronic antibiotic or anti-viral treatment
* Whole blood donation in the last 3 months (\>400 mL of blood) or plans for blood donation during the entire protocol period
* Weight change (intentional or not) over the last 6-months more than 5% of body weight, or plan to lose weight during the study
* Allergy to lidocaine or epinephrine, or other local anaesthetics
* Previous participation to studies where PET or CT method is used
* Use of any medication that, in the opinion of local clinician/researcher, would negatively impact or mitigate full participation and completion, or could influence the study results. This especially applies to the use of β or α adrenergic receptors agonists/antagonists (e.g., β-blockers).
* Any other cardiovascular, pulmonary, orthopaedic, neurologic, psychiatric or other conditions that, in the opinion of the local clinician/researcher, would preclude participation and successful completion of the protocol, or that would negatively impact or mitigate participation in and completion of the protocol

Where it's running

• Turku PET Centre
  Turku, Finland Recruiting

Study contacts

• Principal investigator: Mueez U-Din, PhD — Turku PET Centre, Turku University Hospital
• Study coordinator: Mueez U-Din, PhD
• Email: mueez.udin@utu.fi
• Phone: +358-417027723

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Asprosin and miRNA Profiles in Young Women with Metabolic Syndrome

  This study tests whether certain blood biomarkers, including asprosin and six microRNAs, differ between young women with metabolic syndrome and healthy peers.

  Recruiting University of Applied Sciences in Nowy Targ · Nowy Targ, Lesser Poland Voivodeship · NCT07917364

• Orforglipron in adults with overweight at risk for obesity-related problems

  This study tests whether orforglipron can help people who are overweight and have early signs of metabolic or cardiovascular risk.

  Recruiting at 88 sites Phase 3 Eli Lilly and Company · Anniston, Alabama and 179 other locations · NCT07794579

• Understanding Circadian Rhythms in Human Fat Tissue

  This study is testing how different eating patterns affect the natural body clock of fat cells in people with and without obesity.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06891534

• Investigating body fat distribution and its impact on metabolic diseases in Japanese adults

  This study looks at how the way body fat is distributed affects the risk of metabolic and heart diseases in Japanese adults.

  Recruiting Osaka Metropolitan University · Sakai, Osaka · NCT06694012

• Evaluating Cholestyramine's Effect on Obese Women Before Bariatric Surgery

  This study is testing if a medication called cholestyramine can help reduce harmful chemicals in the bodies of obese women before they have weight loss surgery.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice, Alpes-Mritimes · NCT05966727

• Effects of menopause and aging on weight gain and fat distribution

  This study is testing how menopause affects weight gain and belly fat in women by looking at hormones and seeing if adjusting these hormones can help reduce fat.

  Recruiting Phase 4 University of Colorado, Denver · Aurora, Colorado · NCT04043520

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.